Ligand News and Research

RSS

Unique, tiny protein cage developed to deliver chemotherapy chemicals directly to cancer cells

Washington State University researchers have developed a unique, tiny protein cage to deliver nasty chemotherapy chemicals directly to cancer cells. Direct delivery could improve treatment and lessen what can be horrendous side effects from toxic drugs.

27 Oct 2015

Nivolumab vs docetaxel updated results for nonsquamous, squamous NSCLC

Follow-up results from two trials of the programmed death 1 receptor inhibitor nivolumab versus docetaxel in patients with advanced non-small cell lung cancer were reported at a proffered paper session held at the European Cancer Congress in Vienna, Austria.

23 Oct 2015

Early trial results in lung cancer

Results from early phase trials investigating different therapeutic agents in lung cancer patients were presented during the third Presidential Session at the European Cancer Congress in Vienna, Austria. Here we summarise two studies reported at the session.

22 Oct 2015

Novel ligand peptide-mimic inhibits abnormal overgrowth of blood vessels, may lead to new anti-cancer drugs

An international research team led by scientists at the University of New Mexico Cancer Center discovered and developed a novel ligand peptide-mimic that inhibits abnormal overgrowth of blood vessels in retinal diseases and tumors. The discovery could lead to new drugs that keep cancers from growing. The team published a paper in the journal Science Translational Medicine.

15 Oct 2015

Research on investigational menopause drug wins first prize

Sermonix Pharmaceuticals LLC, a specialty pharmaceutical company focused on the development and commercialization of emerging late-stage women’s health products, today announced it received top honors for its research on investigational drug lasofoxifene at the 26th annual North American Menopause Society (NAMS) meeting in Las Vegas last week.

9 Oct 2015

Quest Diagnostics provides PD-L1 IHC 22C3 PharmDx test service for NSCLC patients

Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced that it will provide clinical laboratory testing using the PD-L1 IHC 22C3 PharmDx immunohistochemistry companion diagnostic.

From Quest Diagnostics 7 Oct 2015

Cabozantinib, nivolumab ‘bring hope’ for advanced RCC patients

Clinical trial results suggest significant benefits with the use of cabozantinib or nivolumab over everolimus for patients with advanced renal cell carcinoma, researchers reported at the European Cancer Congress in Vienna, Austria.

6 Oct 2015

Saint Louis University receives NIH grant to investigate development of new drugs to treat bone diseases

David Griggs, Ph.D., director of biology at Saint Louis University's Center for World Health & Medicine, has received a $1 million R01 grant from the National Institutes of Health to investigate the development of what could be a new class of drugs to treat bone diseases.

30 Sep 2015

Phase II IMvigor 210 data shows atezolizumab may prevent progression of metastatic urothelial bladder cancer

Data presented today at the 2015 European Cancer Congress (ECC) demonstrates that the investigational immunotherapy atezolizumab may prevent progression of metastatic urothelial bladder cancer (mUBC) in all age groups by 2.1 months.

29 Sep 2015

Nivolumab drug improves survival for non-SQ NSCLC patients

Patients with a type of lung cancer called non-squamous non-small cell lung cancer (non-SQ NSCLC) have limited treatment options and a dismal prognosis once their disease has advanced and initial treatment with platinum-based chemotherapy has failed. Second-line treatment is usually with another chemotherapy drug, such as docetaxel or pemetrexed.

28 Sep 2015

Nivolumab drug significantly prolongs survival in advanced kidney cancer patients

The targeted drug nivolumab significantly prolongs survival in patients with advanced kidney cancer, whose disease has progressed after their first treatment, according to results to be presented at the 2015 European Cancer Congress today (Saturday) and published simultaneously in the New England Journal of Medicine.

26 Sep 2015

NUS researchers develop new technique to observe nano-bio interactions

Researchers at the National University of Singapore have developed a technique to observe, in real time, how individual blood components interact and modify advanced nanoparticle therapeutics.

16 Sep 2015

New study reveals role of hydrogen sulfide gas in autoimmune disease

The immune system not only responds to infections and other potentially problematic abnormalities in the body, it also contains a built-in brake in the form of regulatory T cells, or Tregs. Tregs ensure that inflammatory responses don't get out of hand and do damage. In autoimmune diseases, sometimes these Treg cells don't act as they should.

12 Aug 2015

New Tel Aviv University study sheds light on precise trigger of deadly melanoma

Skin cancer is the most common of all cancers, and melanoma, which accounts for 2% of skin cancer cases, is responsible for nearly all skin cancer deaths. Melanoma rates in the US have been rising rapidly over the last 30 years, and although scientists have managed to identify key risk factors, melanoma's modus operandi has eluded the world of medical research.

4 Aug 2015

Regeneron, Sanofi to jointly advance new immuno-oncology treatment options for cancer patients

Regeneron Pharmaceuticals, Inc. and Sanofi have entered into a new global collaboration to discover, develop and commercialize new antibody cancer treatments in the emerging field of immuno-oncology.

28 Jul 2015

Apogenix signs licensing agreement with CANbridge to commercialize APG101 in China, Macao and Hong Kong

Apogenix, a next generation immuno-oncology company, announced today that it has entered into an exclusive licensing agreement with CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, for the development and commercialization of lead immuno-oncology drug candidate APG101 in China, Macao, and Hong Kong.

15 Jul 2015

Computer model shows how cancerous tumors manipulate blood-vessel growth for their own benefit

Rice University researchers have built a simulation to show how cancerous tumors manipulate blood-vessel growth for their own benefit.

9 Jul 2015

Ludwig, CRI launch clinical trials to evaluate immunotherapies for treatment of GBM and solid tumors

Ludwig Cancer Research and the Cancer Research Institute have launched clinical trials evaluating an immunotherapy for the treatment of the brain cancer glioblastoma multiforme (GBM), and a combination of immunotherapies for a variety of solid tumors.

8 Jul 2015

Abide Therapeutics begins Phase 1a study of ABX-1431 investigational endocannabinoid system modulator

Abide Therapeutics, a developer of innovative pharmaceuticals, announced today initiation of enrollment and dosing of the first subject in a Phase 1a clinical study of ABX-1431, a first-in-class, investigational endocannabinoid system modulator.

7 Jul 2015

TSRI scientists devise powerful set of chemical methods to explore protein biology

Scientists at The Scripps Research Institute (TSRI) have devised a powerful set of chemical methods for exploring the biology of proteins.

22 Jun 2015